Oxford BioMedica plc  

(Public, LON:OXB)   Watch this stock  
Find more results for OXB
9.45
-0.25 (-2.58%)
Jul 29 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 9.25 - 9.99
52 week 0.03 - 9.99
Open 9.25
Vol / Avg. 1.41M/4.25M
Mkt cap 242.74M*
P/E     -
Div/yield     -
EPS 0.00*
Shares 2.57B
Beta     -
Inst. own     -
*GBP
Jun 24, 2015
Oxford BioMedica PLC at ROTH Healthcare Day - London
Jun 16, 2015
Oxford BioMedica PLC Annual Shareholders Meeting (Estimated)
Jun 2, 2015
Oxford BioMedica PLC at Jefferies Global Healthcare Conference
May 7, 2015
Oxford BioMedica PLC Annual Shareholders Meeting
  

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -43.41% -63.60%
Operating margin -58.43% -77.93%
EBITD margin - -69.86%
Return on average assets -24.17% -36.51%
Return on average equity -32.53% -54.24%
Employees 113 -
CDP Score - -

Address

Windrush Court,Transport Way
OXFORD, OX4 6LT
United Kingdom - Map
+44-1865-783000 (Phone)
+44-1865-783001 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Oxford BioMedica plc is a United Kingdom-based gene and cell therapy research and development business. The Company is lentiviral vector and cell therapy research, development and manufacture. It provides a platform of technologies and capabilities with which it designs, develops and manufactures gene and cell-based medicines. The Company's clinical pipeline is targeting Parkinson's disease, selected cancers and a number of serious eye diseases. The Company has four clinical programs in active development and two other products, including EncorStat and OXB-102, being readied for Phase I/II. EncorStat is being studied for the prevention of corneal graft rejection. OXB-102 is being studied to target Parkinson's disease.

Officers and directors

John Dawson Chief Executive Officer, Executive Director
Age: 55
Tim Watts Chief Financial Officer, Company Secretary, Executive Director
Age: 57
Paul Blake M.D. Executive Director, Chief Development Officer
Age: 66
Peter Nolan Executive Director, Chief Business Officer
Age: 62
Nicholas Rodgers Non-Executive Independent Chairman of the Board
Age: 56
Andrew J. Heath M.D., Ph.D. Non-Executive Deputy Chairman of the Board, Senior Independent Director
Age: 66
Martin Diggle Non-Executive Director
Age: 52
Daniel B. Soland Non-Executive Director
Age: 56